Tonix Pharmaceuticals Holding Corp

TNXP remains in a Stage 4 decline with successive lower highs and lower lows under declining 50- and 200-day SMAs. Both medium- and long-term biases are bearish and supply continues to dominate demand. Despite short-term EMA repair and an uptrend in the 9/21 EMAs, price remains below major resistance, making sell timing unfavorable now. Under a Speculative strategy, sell-side execution should be deferred, focusing on rejections at the declining 9/21 EMAs and the 50 DMA.

• ↑FDA approval of TONMYA in June 2026 unlocks fibromyalgia market revenue.
• ↑Acute stress trial data due 2H 2026 and Q4 2025 MDD IND filing.
• ↓Negative earnings yield suggests shares may be overvalued.